Patient-specific tumor neoantigen-derived peptide epitope (Neoantigen)

Patient-specific tumor neoantigen-derived peptide epitopes are unique protein fragments arising from somatic mutations—such as non-synonymous single nucleotide variants (SNVs), insertions/deletions (indels), or frameshifts—within a patient's tumor cells (Schumacher & Schreiber, 2015). Unlike tumor-associated antigens, these neoepitopes are not expressed in normal tissues, making them highly specific targets for the immune system and reducing the likelihood of central tolerance (Blass & Ott, 2021). These peptides are processed intracellularly and presented on the cell surface by Major Histocompatibility Complex (MHC) molecules, where they can be recognized by T-cell receptors (TCRs) (Sahin & Türeci, 2018). This recognition triggers a targeted cytotoxic T-cell response against the tumor. Therapeutic approaches leveraging these targets include personalized cancer vaccines (mRNA, DNA, or peptide-based) and adoptive T-cell therapies designed to expand or engineer T cells specific to these neoepitopes (Xie et al., 2023). The clinical utility of these targets depends on accurate genomic sequencing and bioinformatic prediction of peptide-MHC binding affinity and immunogenicity.

Other names

Tumor-specific antigenNeoepitopeSomatic mutation-derived antigenPersonalized tumor antigenTSA

Induction of a de novo T-cell response or expansion of existing neoantigen-specific T cells that recognize and kill tumor cells presenting these unique peptide-MHC complexes (Schumacher & Schreiber, 2015; Blass & Ott, 2021).